Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual resistance to asparaginase and PD-1 blockade in extranodal natural killer/T-cell lymphoma: dismal outcomes from a multicenter cohort.

Haematologica·2026
Same author

Clinical significance of high-density lipoprotein cholesterol and its dynamic change in patients with lymphoma-associated hemophagocytic lymphohistiocytosis.

Therapeutic advances in medical oncology·2026
Same author

Deep-learning-based artificial intelligence approaches for grading and progression prediction of clear cell renal cell carcinoma.

iScience·2026
Same author

Concurrent antiviral-immunochemotherapy strategy safely overcomes high hepatitis B viral load barrier in diffuse large B-cell lymphoma: A multicentre cohort study.

British journal of haematology·2026
Same author

A lipid nanoparticle-based peptide-proteolysis-targeting chimera degrades BCL6 for diffuse large B-cell lymphoma treatment.

Discover oncology·2026
Same author

Application of BCMA CAR-T in systemic lupus erythematosus.

Clinical rheumatology·2026

Related Experiment Video

Updated: Apr 28, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.3K

Outcomes With First-Line PD1 Inhibitors in Extranodal NK/T-Cell Lymphoma: A Comparative Analysis From a 755-Patient

Hailing Liu1,2, Mei Sun3, Chunling Wang4

  • 1Department of Hematology, Jiangsu Province Hospital, the First Affiliated Hospital With Nanjing Medical University, Nanjing, Jiangsu, China.

American Journal of Hematology
|April 26, 2026
PubMed
Summary

Frontline programmed cell death 1 inhibitors (PD1i) significantly improve survival in newly diagnosed extranodal NK/T-cell lymphoma (ENKTL), even in high-risk patients. Combination therapy with asparaginase shows enhanced efficacy and a favorable safety profile.

Keywords:
PD1 inhibitorasparaginaseextranodal NK/T‐cell lymphomafirst‐lineimmunochemotherapyoutcome

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

20.8K
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.9K

Related Experiment Videos

Last Updated: Apr 28, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.3K
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

20.8K
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.9K

Area of Science:

  • Oncology
  • Immunotherapy
  • Hematologic Malignancies

Background:

  • Extranodal NK/T-cell lymphoma (ENKTL) is an aggressive non-Hodgkin lymphoma.
  • Programmed cell death 1 inhibitors (PD1i) are established for relapsed/refractory ENKTL.
  • The efficacy of frontline PD1i in newly diagnosed ENKTL remains uncertain.

Purpose of the Study:

  • To evaluate the effectiveness and safety of first-line programmed cell death 1 inhibitors (PD1i) in newly diagnosed extranodal NK/T-cell lymphoma (ENKTL).
  • To assess the impact of PD1i, particularly in combination with asparaginase, on patient outcomes and survival.
  • To determine if PD1i is an independent prognostic factor in ENKTL treatment.

Main Methods:

  • Retrospective, multi-center study of 755 newly diagnosed ENKTL patients.
  • Comparison of outcomes between patients receiving first-line PD1i and those not.
  • Statistical analyses including Cox regression, propensity score matching, random forest, and multi-state survival modeling.
  • Evaluation of safety data, including toxicities and adverse events.

Main Results:

  • 17.9% of patients received first-line PD1i, often with adverse risk features.
  • PD1i group showed significantly improved progression-free survival (HR=0.62) and overall survival (HR=0.55).
  • PD1i demonstrated independent favorable prognostic value across multiple analytical models.
  • PD1i-asparaginase combination therapy showed a ~50% reduction in event probability, especially in high-risk/advanced stages.
  • PD1i primarily delays disease progression; safety profile was manageable with reduced severe infections.

Conclusions:

  • First-line PD1i therapy significantly improves outcomes in newly diagnosed ENKTL, including high-risk and advanced stages.
  • The combination of PD1i with asparaginase offers enhanced efficacy and a favorable risk-benefit profile.
  • Frontline PD1i warrants consideration for incorporation into ENKTL treatment protocols.
  • Prospective randomized trials are needed to confirm these findings.